HomeCompareHOLX vs MCO

HOLX vs MCO: Dividend Comparison 2026

HOLX yields 2.65% · MCO yields 0.89%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MCO wins by $183.5K in total portfolio value· pulled ahead in Year 3
10 years
HOLX
HOLX
● Live price
2.65%
Share price
$75.55
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$23.6K
Annual income
$314.03
Full HOLX calculator →
MCO
MCO
● Live price
0.89%
Share price
$432.05
Annual div
$3.85
5Y div CAGR
74.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$207.2K
Annual income
$113,279.94
Full MCO calculator →

Portfolio growth — HOLX vs MCO

📍 MCO pulled ahead of the other in Year 3

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodHOLXMCO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, HOLX + MCO cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
HOLX pays
MCO pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

HOLX
Annual income on $10K today (after 15% tax)
$225.02/yr
After 10yr DRIP, annual income (after tax)
$266.93/yr
MCO
Annual income on $10K today (after 15% tax)
$75.74/yr
After 10yr DRIP, annual income (after tax)
$96,287.95/yr
At 15% tax rate, MCO beats the other by $96,021.02/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of HOLX + MCO for your $10,000?

HOLX: 50%MCO: 50%
100% MCO50/50100% HOLX
Portfolio after 10yr
$115.4K
Annual income
$56,796.98/yr
Blended yield
49.21%
📊

Analyst Conviction Gap

Where Wall Street is split right now

HOLX
Analyst Ratings
18
Buy
23
Hold
1
Sell
Consensus: Hold
Price Target
$77.80
+3.0% upside vs current
Range: $76.00 — $79.00
Altman Z
4.2
Piotroski
7/9
MCO
Analyst Ratings
18
Buy
13
Hold
1
Sell
Consensus: Buy
Price Target
$543.08
+25.7% upside vs current
Range: $480.00 — $620.00
Altman Z
5.3
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

HOLX buys
0
MCO buys
0
No recent congressional trades found for HOLX or MCO in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricHOLXMCO
Forward yield2.65%0.89%
Annual dividend / share$2.00$3.85
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%74.8%
Portfolio after 10y$23.6K$207.2K
Annual income after 10y$314.03$113,279.94
Total dividends collected$2.9K$178.5K
Payment frequencyquarterlyquarterly
SectorHealthcareFinancials
Analyst consensusHoldBuy
Analyst price target$77.80$543.08

Year-by-year: HOLX vs MCO ($10,000, DRIP)

YearHOLX PortfolioHOLX Income/yrMCO PortfolioMCO Income/yrGap
1$10,965$264.73$10,856$155.76+$109.00HOLX
2$12,004$271.27$11,892$276.24+$112.00HOLX
3← crossover$13,121$277.55$13,219$494.35$98.00MCO
4$14,323$283.54$15,042$897.70$719.00MCO
5$15,615$289.27$17,763$1,668.77$2.1KMCO
6$17,003$294.73$22,226$3,219.45$5.2KMCO
7$18,493$299.93$30,363$6,580.83$11.9KMCO
8$20,093$304.87$47,175$14,686.41$27.1KMCO
9$21,809$309.57$87,754$37,276.83$65.9KMCO
10$23,649$314.03$207,177$113,279.94$183.5KMCO

HOLX vs MCO: Complete Analysis 2026

HOLXHealthcare

Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load tests for HIV, Hepatitis C, and Hepatitis B; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays for the detection of SARS-CoV-2; ThinPrep System for use in cytology applications; Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth; and various diagnostic tests for the detection of Group B Streptococcus. It also offers breast imaging and analytics, such as 2D and 3D digital mammography systems and reading workstations, minimally invasive breast biopsy guidance systems and devices, breast biopsy site markers and localization, specimen radiology, and ultrasound and connectivity solutions; and breast conserving surgery products. In addition, the company provides NovaSure Endometrial Ablation System for the treatment of abnormal uterine bleeding; MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids, polyps, and other pathology within the uterus; and Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures. Further, it offers Horizon DXA, a dual energy X-ray system; and the Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. The company sells its products through direct sales and service forces, and independent distributors and sales representatives. Hologic, Inc. was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.

Full HOLX Calculator →

MCOFinancials

Moody's Corporation operates as an integrated risk assessment firm worldwide. It operates in two segments, Moody's Investors Service and Moody's Analytics. The Moody's Investors Service segment publishes credit ratings and provides assessment services on various debt obligations, programs and facilities, and entities that issue such obligations, such as various corporate, financial institution, and governmental obligations, as well as and structured finance securities. This segment provides ratings in approximately 140 countries. Its ratings are disseminated through press releases to the public through electronic media, including the internet and real-time information systems used by securities traders and investors. This segment has rated approximately 5,000 non-financial corporates; 3,600 financial institutions; 16,000 public finance issuers; 145 sovereigns; 47 supranational institutions; 459 sub-sovereigns; and 1,000 infrastructure and project finance issuers, as well as 9,100 structured finance deals. The Moody's Analytics segment develops a range of products and services that support the risk management activities of institutional participants in financial markets; and offers subscription based research, data, and analytical products comprising credit ratings, credit research, quantitative credit scores and other analytical tools, economic research and forecasts, business intelligence and company information products, commercial real estate data and analytical tools, and on-line and classroom-based training services, as well as credentialing and certification services. It also offers offshore analytical and research services with learning solutions and certification programs; and software solutions, as well as related risk management services. The company was formerly known as Dun and Bradstreet Company and changed its name to Moody's Corporation in September 2000. Moody's Corporation was founded in 1900 and is headquartered in New York, New York.

Full MCO Calculator →
📬

Get this HOLX vs MCO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

HOLX vs SCHDHOLX vs JEPIHOLX vs OHOLX vs KOHOLX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.